DYRK1A and early-onset autosomal dominant Alzheimer disease: In a recent study, novel prodrugs for Alzheimer’s disease targeting 2 specific targets, dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) and cholinesterase (ChE), were designed and synthesized [48].